Ancora Advisors LLC Grows Holdings in Applied Genetic Technologies Corp (AGTC)

Share on StockTwits

Ancora Advisors LLC grew its stake in Applied Genetic Technologies Corp (NASDAQ:AGTC) by 270.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,154 shares of the biotechnology company’s stock after acquiring an additional 54,154 shares during the period. Ancora Advisors LLC owned 0.41% of Applied Genetic Technologies worth $285,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in AGTC. 683 Capital Management LLC bought a new position in shares of Applied Genetic Technologies in the 4th quarter valued at about $778,000. Municipal Employees Retirement System of Michigan grew its holdings in shares of Applied Genetic Technologies by 66.7% in the 4th quarter. Municipal Employees Retirement System of Michigan now owns 311,820 shares of the biotechnology company’s stock valued at $1,123,000 after acquiring an additional 124,810 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Applied Genetic Technologies by 24.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 632,540 shares of the biotechnology company’s stock valued at $2,435,000 after acquiring an additional 124,422 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Applied Genetic Technologies by 32.5% in the 4th quarter. Renaissance Technologies LLC now owns 444,428 shares of the biotechnology company’s stock valued at $1,600,000 after acquiring an additional 109,128 shares in the last quarter. Finally, Spark Investment Management LLC grew its holdings in shares of Applied Genetic Technologies by 122.1% in the 4th quarter. Spark Investment Management LLC now owns 107,700 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 59,200 shares in the last quarter. Institutional investors own 44.85% of the company’s stock.

Applied Genetic Technologies stock opened at $4.55 on Thursday. Applied Genetic Technologies Corp has a 52 week low of $3.25 and a 52 week high of $6.05. The stock has a market cap of $79.69 million, a P/E ratio of 227.50 and a beta of 2.06.

Applied Genetic Technologies (NASDAQ:AGTC) last posted its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.04). Applied Genetic Technologies had a negative return on equity of 16.00% and a negative net margin of 65.96%. The business had revenue of $3.60 million for the quarter, compared to the consensus estimate of $6.41 million. analysts forecast that Applied Genetic Technologies Corp will post -1.19 EPS for the current fiscal year.

Several equities analysts have recently weighed in on AGTC shares. ValuEngine cut Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Zacks Investment Research upgraded Applied Genetic Technologies from a “sell” rating to a “hold” rating in a report on Friday, March 30th. Finally, HC Wainwright set a $8.00 price objective on Applied Genetic Technologies and gave the company a “buy” rating in a report on Wednesday, May 9th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $9.00.

Applied Genetic Technologies Profile

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.

Want to see what other hedge funds are holding AGTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Applied Genetic Technologies Corp (NASDAQ:AGTC).

Institutional Ownership by Quarter for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply